Artikel ; Online: Cisplatin in the era of PARP inhibitors and immunotherapy.
2024 Band 258, Seite(n) 108642
Abstract: Platinum compounds such as cisplatin, carboplatin and oxaliplatin are widely used in chemotherapy. Cisplatin induces cytotoxic DNA damage that blocks DNA replication and gene transcription, leading to arrest of cell proliferation. Although platinum ... ...
Abstract | Platinum compounds such as cisplatin, carboplatin and oxaliplatin are widely used in chemotherapy. Cisplatin induces cytotoxic DNA damage that blocks DNA replication and gene transcription, leading to arrest of cell proliferation. Although platinum therapy alone is effective against many tumors, cancer cells can adapt to the treatment and gain resistance. The mechanisms for cisplatin resistance are complex, including low DNA damage formation, high DNA repair capacity, changes in apoptosis signaling pathways, rewired cell metabolisms, and others. Drug resistance compromises the clinical efficacy and calls for new strategies by combining cisplatin with other therapies. Exciting progress in cancer treatment, particularly development of poly (ADP-ribose) polymerase (PARP) inhibitors and immune checkpoint inhibitors, opened a new chapter to combine cisplatin with these new cancer therapies. In this Review, we discuss how platinum synergizes with PARP inhibitors and immunotherapy to bring new hope to cancer patients. |
---|---|
Mesh-Begriff(e) | Humans ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; Neoplasms/drug therapy ; Neoplasms/immunology ; Cisplatin/therapeutic use ; Cisplatin/pharmacology ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/pharmacology ; Immunotherapy/methods ; Animals ; Drug Resistance, Neoplasm ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Inhibitors/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology |
Chemische Substanzen | Poly(ADP-ribose) Polymerase Inhibitors ; Cisplatin (Q20Q21Q62J) ; Antineoplastic Agents ; Immune Checkpoint Inhibitors |
Sprache | Englisch |
Erscheinungsdatum | 2024-04-16 |
Erscheinungsland | England |
Dokumenttyp | Journal Article ; Review |
ZDB-ID | 194735-7 |
ISSN | 1879-016X ; 0163-7258 |
ISSN (online) | 1879-016X |
ISSN | 0163-7258 |
DOI | 10.1016/j.pharmthera.2024.108642 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.A 1183: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.